Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01479
|
|||||
| Drug Name |
Debrisoquine
|
|||||
| Synonyms |
Debrisochinum; Debrisoquina; Debrisoquine; Debrisoquinum; Declinax; Equitonil; Isocaramidine; Tendor; DEBRISOQUIN SULFATE; Debrisoquin hemisulfate; Debrisoquine sulfate; Isocaramidine sulfate; Debrisoquina [INN-Spanish]; Debrisoquine [INN:BAN]; Debrisoquinum [INN-Latin]; Ro 5-3307/1; Sulfuric acid compound with 3,4-dihydro-2(1H)-isoquinolinecarboximidamide (1:1); 1,2,3, 4-Tetrahydro-isoquinoline-2-carboxamidine sulfate; 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-(7CI,8CI); 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-, sulfate (2:1); 2(1H)-Isoquinolinecarboximidamide, 3,4-dihydro-, sulfate (2:1); 2-Amidino-1,2,3,4-tetrahydroisoquinoline; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine sulfate (2:1); 3,4-Dihydro-2(1H)-isoquinolinecarboximidamide; 3,4-Dihydro-2(1H;)-isoquinoline carboxamidine sulfate; 3,4-dihydro-1H-isoquinoline-2-carboximidamide; 3,4-dihydroisoquinoline-2(1H)-carboximidamide
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hypertension [ICD11: BA00] | Approved | [1] | |||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C10H13N3
|
|||||
| Canonical SMILES |
C1CN(CC2=CC=CC=C21)C(=N)N
|
|||||
| InChI |
InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)
|
|||||
| InChIKey |
JWPGJSVJDAJRLW-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 1131-64-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 175.23 | Topological Polar Surface Area | 53.1 | ||
| Heavy Atom Count | 13 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 1 | |||
| XLogP |
0.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
794638
, 841242
, 5535330
, 7846928
, 7979030
, 8151889
, 11112418
, 11466400
, 11467520
, 11486180
, 14968163
, 29222116
, 46507664
, 47291325
, 47589190
, 47885609
, 48110673
, 48334720
, 48415845
, 49698461
, 50064178
, 50100434
, 50100435
, 50715101
, 53787958
, 56394850
, 57321534
, 57872971
, 81121137
, 88560042
, 92308985
, 103426282
, 104015275
, 104302135
, 104773785
, 125689076
, 126525753
, 128338031
, 131290193
, 134337449
, 134980804
, 137014737
, 142987200
, 143633555
, 160967816
, 162776450
, 164844863
, 170049193
, 172913429
, 176484158
|
|||||
| ChEBI ID |
ChEBI:34665
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | National Center for Advancing Translational Science-Inxight: drug (X31CDK040E) | |||||
| 2 | The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Biochem Pharmacol. 2012 May 15;83(10):1427-34. | |||||
| 3 | Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.